WebDoctor Encyclopedia

Plasma-cell neoplasms

AL amyloidosis

AL amyloidosis is a rare disorder in which abnormal plasma cells make light chains that fold into amyloid and build up in organs such as the heart and kidneys. Early diagnosis is vital because heart damage decides the outlook.

Medically reviewed Last reviewed October 27, 2026

What is AL amyloidosis?

AL amyloidosis is a rare disease in which an abnormal protein called amyloid builds up in the body’s organs and stops them working properly. “AL” stands for amyloid light chain.

The problem starts in the bone marrow. A small group (clone) of abnormal plasma cells, the white blood cells that normally make antibodies, produces too much of one antibody fragment called a light chain.

These light chains are misshapen. Instead of being cleared from the body, they fold into stiff fibres that settle in tissues, much like a build-up of scale in a pipe.

The organs most often affected are the heart and kidneys. The liver, nerves, gut and soft tissues can also be involved.

AL amyloidosis is related to multiple myeloma, but in most people the plasma cell clone is small. The harm comes from the amyloid deposits rather than from a large tumour.

Symptoms are often vague, so diagnosis is frequently delayed. Early diagnosis matters, because treatment works best before organs, particularly the heart, are badly damaged.

1. Key facts at a glance

Feature Details
Type of disease Plasma cell disorder with amyloid deposits in organs
How common About 10-12 new cases per million people each year
Typical age Median about 63-65; rare under 40
Sex Slightly more common in men
Organs most affected Heart (about 70%), kidneys (about 60%), liver, nerves, gut, soft tissues
Link with myeloma About 10-15% also have multiple myeloma
Main treatment Daratumumab-based chemotherapy; stem cell transplant for some
Outlook Depends mainly on the degree of heart involvement

2. Causes and risk factors

AL amyloidosis is caused by a clone of plasma cells making abnormal light chains. Why the clone develops is not known.

It is not infectious and is not inherited. This is different from some other types of amyloidosis, such as hereditary ATTR amyloidosis.

Risk factor Notes
Age Most people are over 50
MGUS A monoclonal protein in the blood (MGUS) can precede AL amyloidosis
Multiple myeloma Some people with myeloma develop AL amyloidosis
Light-chain type About three-quarters of cases involve lambda light chains

Other types of amyloidosis

AL is only one of several types of amyloidosis. Correct typing is essential because treatment is completely different for each.

Type Protein Main cause
AL Immunoglobulin light chain Abnormal plasma cell clone
ATTR wild-type Transthyretin Ageing; mainly the heart in older men
ATTR hereditary Transthyretin Inherited gene change
AA Serum amyloid A Long-term inflammation or infection
Others Various Rare inherited types

3. How does it look

Amyloid deposits are microscopic, but in some people they cause visible signs. These can be important clues for doctors.

Visible sign Description
Bruising around the eyes Purple patches around the eyes (periorbital purpura), sometimes after coughing or straining; called “raccoon eyes”
Large tongue (macroglossia) Enlarged, firm tongue, often with tooth marks along the edges; seen in about 10-20%
Easy bruising Bruises on the neck, face or skin folds from fragile blood vessels
Swollen legs and ankles Fluid build-up from kidney or heart involvement
Enlarged glands under the jaw Firm swelling of the salivary glands
“Shoulder pad” sign Firm swelling over the shoulders from amyloid in soft tissues
Nail changes Brittle, ridged or thickened nails
Waxy skin bumps Small, shiny, yellowish papules, often around the eyes or in skin folds

Under the microscope

In a tissue sample, amyloid looks like a pink, glassy material between cells. When stained with Congo red dye and viewed under polarised light, it shines with a characteristic apple-green colour. This is the classic test for amyloid.

On heart scans

On an echocardiogram, the heart walls appear thickened and stiff, though the heart is not pumping harder. A special measurement (strain imaging) often shows a pattern that spares the tip of the heart.

Cardiac MRI may show a typical pattern of enhancement after contrast dye.

4. Symptoms

Symptoms depend on which organs are affected. They often develop slowly and can easily be mistaken for more common conditions.

General symptoms

  • Extreme tiredness and weakness
  • Unexplained weight loss
  • Loss of appetite

Heart symptoms

  • Breathlessness, especially on exertion or when lying flat
  • Swelling of the ankles, legs or abdomen
  • Palpitations or an irregular heartbeat
  • Dizziness or fainting, sometimes on standing up

Kidney symptoms

  • Foamy urine from protein leaking into it
  • Swelling of the legs, around the eyes and elsewhere (nephrotic syndrome)
  • Later, reduced kidney function

Nerve symptoms

  • Numbness, tingling or burning in the feet and hands
  • Carpal tunnel syndrome, often in both wrists
  • Light-headedness on standing from low blood pressure
  • Erectile dysfunction
  • Bowel or bladder problems

Gut and liver symptoms

  • Diarrhoea or constipation, sometimes alternating
  • Feeling full quickly or nausea
  • An enlarged liver, sometimes felt as fullness under the right ribs
  • Bleeding from the gut in some cases

When to see a doctor

See a doctor if you have unexplained breathlessness, swollen legs, foamy urine or numb feet, especially if more than one is present. Doctors should consider AL amyloidosis in anyone with a known monoclonal protein (MGUS) who develops these symptoms.

5. Diagnosis

Diagnosing AL amyloidosis requires three steps: proving amyloid is present, confirming its type is AL and measuring which organs are affected.

Step Tests
Find the abnormal light chain Serum and urine immunofixation; serum free light chain test
Prove amyloid is present Biopsy of abdominal fat, bone marrow or an affected organ, stained with Congo red
Confirm the type Mass spectrometry or immunoelectron microscopy on the biopsy (Vrana et al., 2009)
Assess the bone marrow Bone marrow biopsy to measure plasma cells and check for myeloma
Assess the heart NT-proBNP and troponin blood tests, ECG, echocardiogram, cardiac MRI
Assess the kidneys Urine protein measurement, kidney function blood tests
Assess the liver Alkaline phosphatase blood test, liver scan
Assess the nerves Nerve conduction studies if symptoms are present

A fat pad biopsy is simple and done with a needle under local anaesthetic. It finds amyloid in roughly three-quarters of people with AL amyloidosis.

Typing matters because finding a monoclonal protein does not prove the amyloid is AL. MGUS is common in older people, who may have ATTR amyloidosis at the same time.

6. Staging

Staging is based on blood markers of heart damage and the amount of abnormal light chain. It is the best guide to outlook and helps doctors choose safe treatment.

Revised Mayo staging (2012)

Each of the following counts as one point (Kumar et al., 2012):

  • Troponin T 0.025 ng/mL or higher
  • NT-proBNP 1800 pg/mL or higher
  • Difference between involved and uninvolved free light chains 180 mg/L or higher
Stage Points Median survival in the original study
I 0 About 8 years
II 1 About 3.4 years
III 2 About 1 year
IV 3 About 6 months

Survival has improved since this system was developed, thanks to newer treatments. Many centres also use the earlier Mayo 2004 heart staging, with its European modification for very advanced heart involvement (Dispenzieri et al., 2004).

Kidney staging

A separate kidney staging system uses kidney function (eGFR) and the amount of protein in the urine. It predicts the risk of needing dialysis (Palladini et al., 2014).

7. Treatment

The aim of treatment is to switch off the plasma cell clone so it stops making the harmful light chains. Once the supply stops, organs can stabilise and often slowly recover as the body clears some of the amyloid.

Treatment should be given at a specialist amyloidosis centre where possible.

First treatment

Treatment Notes
Daratumumab + bortezomib + cyclophosphamide + dexamethasone (Dara-VCd) Current standard first treatment; in the ANDROMEDA trial it more than doubled the rate of complete blood responses compared with VCd alone (Kastritis et al., 2021)
High-dose melphalan with autologous stem cell transplant For carefully selected fitter people, roughly 1 in 5; offers deep, long-lasting responses
Reduced-intensity regimens For frail patients or those with severe heart involvement

Treatment if the disease returns

Option Notes
Daratumumab (if not used before) Effective as a single drug or in combination
Lenalidomide or pomalidomide with dexamethasone Used for relapse; lower doses are needed in AL
Venetoclax Effective in people whose plasma cells carry the t(11;14) change, found in about half (Premkumar et al., 2021)
Clinical trials Including antibodies designed to clear amyloid deposits and new targeted treatments

Supportive care

Supportive care is just as important as treating the clone.

Problem Supportive treatment
Fluid build-up Diuretics (water tablets), salt restriction, compression stockings
Low blood pressure Midodrine, compression stockings; some heart drugs must be avoided
Irregular heartbeat Specialist cardiology care; sometimes a pacemaker or defibrillator
Kidney failure Dialysis; kidney transplant in selected people after good response
Nerve pain Medicines such as gabapentin or duloxetine
Diarrhoea Anti-diarrhoea medicines and nutrition support

Some people with severe heart damage but an otherwise good response may be considered for a heart transplant followed by treatment of the clone.

Measuring response

Doctors measure the free light chain level to check how well the clone has been suppressed (Palladini et al., 2012). They also track NT-proBNP and urine protein to see whether the heart and kidneys are improving.

Organ improvement often lags behind the blood response by months to a year or more.

8. Outlook (prognosis)

The outlook varies greatly. The extent of heart involvement is the single most important factor.

Situation Typical outlook
No or mild heart involvement, good response Many people live 10 years or more
Moderate heart involvement Several years with effective treatment
Very advanced heart involvement High risk of death in the first months; survival often under 1 year
Deep (complete) blood response Linked with organ recovery and longer survival

A significant number of deaths happen in the first few months after diagnosis, mostly in people with advanced heart disease. This is why early recognition is so important (Gertz, 2024).

9. Living with AL amyloidosis

  • Diet: a low-salt diet helps control fluid; a dietitian can help with weight loss and gut symptoms
  • Fluids: your team may advise limits on how much you drink
  • Activity: gentle, regular activity helps, but avoid sudden heavy exertion if your heart is affected
  • Daily weight: weigh yourself every morning; a quick gain can signal fluid build-up
  • Standing up slowly: helps avoid dizziness from low blood pressure
  • Medicine review: some common heart and blood pressure drugs can be poorly tolerated in amyloidosis
  • Support: patient organisations offer information, peer support and help with practical matters

10. Frequently asked questions

Question Answer
Is AL amyloidosis cancer? It is a blood disorder closely related to myeloma and is treated with similar drugs, but most people do not have myeloma
Is it inherited? No. AL amyloidosis is not passed on in families
Can the organs recover? Often partly, once the light chain supply is stopped, but recovery is slow
Will I need lifelong treatment? Treatment is usually given for a set period; many people then stay on monitoring only
Can it come back? Yes, so regular blood tests continue for life

11. Questions to ask your care team

  • Has my amyloid been typed to confirm it is AL?
  • Which organs are affected, and what is my stage?
  • Which treatment do you recommend, and am I suitable for a stem cell transplant?
  • How will we know whether treatment is working?
  • Which medicines should I avoid?
  • Are there clinical trials I could join?

Resources

  1. Gertz, M.A. (2024) ‘Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment’, American Journal of Hematology, 99(2), pp. 309-324.
  2. Merlini, G. et al. (2018) ‘Systemic immunoglobulin light chain amyloidosis’, Nature Reviews Disease Primers, 4(1), p. 38.
  3. Kastritis, E. et al. (2021) ‘Daratumumab-based treatment for immunoglobulin light-chain amyloidosis’, New England Journal of Medicine, 385(1), pp. 46-58.
  4. Kumar, S. et al. (2012) ‘Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements’, Journal of Clinical Oncology, 30(9), pp. 989-995.
  5. Dispenzieri, A. et al. (2004) ‘Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis’, Journal of Clinical Oncology, 22(18), pp. 3751-3757.
  6. Palladini, G. et al. (2012) ‘New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes’, Journal of Clinical Oncology, 30(36), pp. 4541-4549.
  7. Palladini, G. et al. (2014) ‘A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis’, Blood, 124(15), pp. 2325-2332.
  8. Vrana, J.A. et al. (2009) ‘Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens’, Blood, 114(24), pp. 4957-4959.
  9. Wechalekar, A.D. et al. (2023) ‘Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group’, Amyloid, 30(1), pp. 3-17.
  10. Premkumar, V.J. et al. (2021) ‘Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis’, Blood Cancer Journal, 11(1), p. 10.

Prepared by the editorial team, October 2026.